Hussman Strategic Advisors Inc. Makes New Investment in iRhythm Technologies $IRTC

Key Points

• Hussman Strategic Advisors established a new position in iRhythm, buying 14,700 shares worth approximately $2.61 million in the fourth quarter.
• iRhythm beat Q1 estimates with $199.4M revenue (up 25.6% YoY) and EPS of -$0.35, issued FY2026 revenue guidance of about $875–$885M, and drew mixed analyst reactions leaving a consensus rating of Moderate Buy (consensus PT $197.77).
• Company insiders sold a total of 94,509 shares (~$12.7M) over the last quarter, lowering insider ownership to 1.10%, while the stock traded down about 6.5% to roughly $120.80.

Hussman Strategic Advisors Inc. bought a new position in shares of iRhythm Technologies (NASDAQ:IRTC - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 14,700 shares of the company's stock, valued at approximately $2,608,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Measured Wealth Private Client Group LLC bought a new stake in iRhythm Technologies during the 3rd quarter worth approximately $30,000. Root Financial Partners LLC bought a new stake in iRhythm Technologies during the 3rd quarter worth approximately $30,000. GAMMA Investing LLC increased its stake in iRhythm Technologies by 48.4% during the 4th quarter. GAMMA Investing LLC now owns 184 shares of the company's stock worth $33,000 after purchasing an additional 60 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in iRhythm Technologies by 100.0% during the 3rd quarter. Smartleaf Asset Management LLC now owns 198 shares of the company's stock worth $34,000 after purchasing an additional 99 shares in the last quarter. Finally, FNY Investment Advisers LLC bought a new stake in iRhythm Technologies during the 3rd quarter worth approximately $34,000.

Insider Activity at iRhythm Technologies

In other news, insider Patrick Michael Murphy sold 4,357 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $128.44, for a total transaction of $559,613.08. Following the sale, the insider owned 63,203 shares in the company, valued at $8,117,793.32. This represents a 6.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Chad Patterson sold 4,444 shares of the company's stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $128.44, for a total value of $570,787.36. Following the sale, the insider owned 58,164 shares in the company, valued at approximately $7,470,584.16. This represents a 7.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 94,509 shares of company stock worth $12,734,195. Insiders own 1.10% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on IRTC shares. Needham & Company LLC increased their target price on iRhythm Technologies from $254.00 to $255.00 and gave the stock a "buy" rating in a research note on Friday. Canaccord Genuity Group lowered their target price on iRhythm Technologies from $198.00 to $180.00 and set a "buy" rating for the company in a research note on Friday. JPMorgan Chase & Co. lowered their target price on iRhythm Technologies from $215.00 to $175.00 and set an "overweight" rating for the company in a research note on Friday. Wall Street Zen raised iRhythm Technologies from a "hold" rating to a "buy" rating in a research note on Sunday. Finally, Morgan Stanley reissued an "overweight" rating on shares of iRhythm Technologies in a research note on Monday, January 12th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $197.77.

iRhythm Technologies Trading Down 6.5%

NASDAQ IRTC opened at $120.80 on Friday. The stock has a market capitalization of $3.97 billion, a price-to-earnings ratio of -140.46 and a beta of 1.33. The stock's 50 day moving average price is $122.93 and its two-hundred day moving average price is $154.44. The company has a debt-to-equity ratio of 4.25, a quick ratio of 4.48 and a current ratio of 4.63. iRhythm Technologies has a 52 week low of $112.31 and a 52 week high of $212.00.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.21. iRhythm Technologies had a negative return on equity of 10.97% and a negative net margin of 3.53%.The company had revenue of $199.39 million for the quarter, compared to analysts' expectations of $194.11 million. During the same quarter in the prior year, the business posted ($0.97) EPS. The business's revenue was up 25.6% compared to the same quarter last year. As a group, analysts anticipate that iRhythm Technologies will post -0.16 earnings per share for the current fiscal year.

iRhythm Technologies News Summary

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q1 results beat on revenue and EPS trends: iRhythm reported $199.4M in revenue (up 25.6% YoY) and a loss per share that was smaller than expected, indicating improving unit economics and topline momentum. This supports longer‑term growth expectations. IRTC Q1 results and call (MarketBeat)
• Positive Sentiment: Needham raised its price target slightly to $255 and keeps a "buy" rating, signaling conviction from at least one growth‑oriented shop and providing a bullish anchor for longer‑term upside. Needham raises PT to $255 (Benzinga)
• Neutral Sentiment: Company guidance: iRhythm issued FY2026 revenue guidance (~$875–$885M) roughly in line with consensus, which is steady but not clearly bullish; EPS guidance was not meaningfully changed. Guidance that meets expectations can temper upside momentum. IRTC Q1 financial results press release (GlobeNewswire)
• Neutral Sentiment: Additional context available from the Q1 earnings call transcript and analyst previews/deep dives — useful for investors evaluating margin progression, reimbursement/regulatory updates and AI initiatives but not immediate price catalysts by themselves. Q1 earnings call transcript (Seeking Alpha)
• Negative Sentiment: Analyst price‑target cuts from JPMorgan (PT lowered to $175 from $215) and Wells Fargo (PT lowered to $180 from $200) are exerting immediate downward pressure by reducing visible upside and prompting some investors to trim positions. JPMorgan & Wells Fargo lower PTs (Benzinga)
• Negative Sentiment: Truist and other outlets flagged cuts to targets in their Q1 previews, adding to the sell‑side pushback; persistent negative margins and a negative return on equity keep valuation sensitive to near‑term profitability improvements. Truist cuts PT on IRTC (Yahoo Finance)

iRhythm Technologies Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company's flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm's digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.